Efficacy of Nivolumab for Head and Neck Cancer Patients with Primary Sites and Histological Subtypes Excluded from the CheckMate-141 Trial.
Yasuyoshi SatoNaoki FukudaXiaofei WangTetsuya UrasakiAkihiro OhmotoKenji NakanoMayu YunokawaMakiko OnoYukiko SatoHiroki MitaniJunichi TomomatsuShunji TakahashiPublished in: Cancer management and research (2020)
No significant difference in response rates or survival outcomes was detected between nivolumab-treated HNC patients with primary sites and histological subtypes that were included versus excluded in the CheckMate-141 trial. These data provide a potential rationale for nivolumab therapy for all HNC patients in clinical practice.